|1.||Baldrick, Paul: 4 articles (08/2012 - 07/2004)|
|2.||Drachenberg, K J: 3 articles (09/2003 - 06/2001)|
|3.||Wheeler, A W: 3 articles (12/2001 - 06/2001)|
|4.||Elliott, G T: 3 articles (09/2000 - 03/2000)|
|5.||Klaus, Stephan: 2 articles (11/2014 - 07/2003)|
|6.||Bahlmann, Ludger: 2 articles (11/2014 - 07/2003)|
|7.||Gliemroth, Jan: 2 articles (11/2014 - 07/2003)|
|8.||Guo, Zhongwu: 2 articles (05/2014 - 10/2009)|
|9.||de Coppet, Pierre: 2 articles (11/2013 - 01/2010)|
|10.||Roquilly, Antoine: 2 articles (11/2013 - 01/2010)|
08/01/2013 - "The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. "
01/01/2011 - "The ultra-short course pre-seasonal allergy vaccine, containing appropriate allergoids with the adjuvant monophosphoryl lipid A (MPL), may be effective in treating allergic symptoms. "
12/01/2004 - "One approach is to use adjuvants such as immunostimulatory sequences or monophosphoryl lipid A, which can deviate allergy-associated Th2 immune responses towards a Th1 phenotype. "
06/01/2001 - "A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections."
01/01/1995 - "The ability of monophosphoryl lipid A (MLA) to provide prophylactic protection against septic shock was evaluated in a mouse model of induced endotoxin hypersensitivity. "
07/01/1993 - "In contrast to LPS, monophosphoryl lipid A completely failed to induce protection against lethal infection. "
05/01/2014 - "Surprisingly, monophosphoryl lipid A (MPLA), another TLR4 ligand, enhanced clonal expansion of effector CD8(+) T cells, but it also promoted their terminal differentiation and contraction; thus, fewer memory CD8(+) T cells formed, and MPLA-primed animals were less protected against secondary infection compared with those primed with LPS. "
03/14/2014 - "We previously demonstrated that the severe cytokine storm and pathology associated with RSV infection following intramuscular vaccination of cotton rats with FI-RSV Lot 100 could be completely abolished by formulating the vaccine with the mild TLR4 agonist and adjuvant, monophosphoryl lipid A (MPL). "
12/01/2013 - "Monophosphoryl lipid A (MPLA) is well known as a potent adjuvant to enhance immune responses against virus infection. "
10/01/1992 - "Monophosphoryl lipid A enhanced the suppression of splenic infection when given with the BCSP vaccine, but not when given with the PKLPS vaccine. "
06/01/2005 - "Our results suggest that preconditioning with a single dose of monophosphoryl lipid A may attenuate ischemia-related wound healing complications, which may be related to an improvement in perfusion and oxygenation of this tissue. "
08/01/1991 - "We hypothesized that low-dose pretreatment of an intact animal with a nontoxic derivative of endotoxin, monophosphoryl lipid A (MPL), would induce protection against cardiac ischemia/reperfusion (I/R) injury. "
07/01/2003 - "The objective of the present study was to examine the effect of monophosphoryl lipid A on endothelial function and ischemia-reperfusion-induced myocardial injury in the rats treated with LDL. "
01/01/1996 - "The aim of this study was to evaluate the ability of monophosphoryl lipid A (MLA) to preserve global cardiac function and peripheral hemodynamics in a rabbit model of prolonged regional ischemia (90 min), and reperfusion (6 h). "
08/01/1998 - "We studied whether monophosphoryl lipid A (MLA), an endotoxin derivative, protected the heart from planned ischemia in hypercholesterolemic conscious rabbits. "
|4.||Seasonal Allergic Rhinitis (Hay Fever)
10/01/2006 - "To study the safety of intranasal CRX-675 treatment in patients with seasonal allergic rhinitis. "
09/01/2003 - "Specific immunotherapy (SIT) with pollen allergoids formulated with the Th1-inducing adjuvant 3-deacylated monophosphoryl lipid A (MPL adjuvant, Corixa) has shown good efficacy and tolerability in the treatment of pollen allergies in adults. "
08/01/2012 - "A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy."
11/01/2011 - "Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL(®)) for the treatment of grass pollen allergy."
07/01/2004 - "Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy."
07/15/1994 - "Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside."
05/28/2014 - "Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers."
08/01/2002 - "Five groups were studied (n=20/group) : AC, OP, OP + Monophosphoryl Lipid A (MPLA), OP + lysed tumor cells (LTC), or OP + MPLA + LTC. "
04/01/2002 - "Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer."
01/01/2014 - "Moreover, F37A, but not an epitopic peptide, invoked cellular immunity when injected together with monophosphoryl lipid A (MPL), and retarded tumor growth in mice. "
|1.||aluminum sulfate (alum)
|2.||Cell Wall Skeleton
|5.||Toll-Like Receptor 4
|9.||QS 21 (QS21)
|10.||Nitric Oxide (Nitrogen Monoxide)
|5.||Transplantation (Transplant Recipients)